PepGen (NASDAQ:PEPG) Announces Quarterly Earnings Results

PepGen (NASDAQ:PEPG) released its quarterly earnings results on Monday. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13, Zacks reports.

PepGen Stock Down 4.9 %

Shares of NASDAQ:PEPG opened at $1.37 on Monday. The company has a market cap of $44.66 million, a P/E ratio of -0.46 and a beta of 1.53. The business has a fifty day simple moving average of $2.56 and a 200-day simple moving average of $5.87. PepGen has a 52 week low of $1.16 and a 52 week high of $19.30.

Wall Street Analysts Forecast Growth

PEPG has been the subject of a number of recent research reports. HC Wainwright dropped their price objective on PepGen from $26.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Wedbush decreased their price target on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Monday, December 16th.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.